The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2016 | Why hematologists should use social media
Michael Thompson, MD, PhD of the Aurora Health Care, Milwaukee, WI discusses why hematologists should use social media. First Dr Thompson addresses some of the common reservations medical professionals might have about using social media. He then talks about its benefits, such as receiving highly curated information from other Twitter users, discussing opinions and influencing other people to affect change.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
